Table 1. Clinical characteristic of 77 patients with Ph+ ALL.
| Total | 1st-generation TKI | 2nd-generation TKIs | P-value | |
|---|---|---|---|---|
| Patients (N) | 77 | 45 | 32 | |
| Median age (years) (range) | 30 (13-59) | 28 (13-59) | 32 (14-59) | 0.135 |
| Gender, male/female (ratio) | 52/25 (2.1) | 28/17(1.6) | 24/8 (3.0) | 0.238 |
| WBC count (×109/L) | 61.7(0.7-517.0) | 77.5 (0.7-352.0) | 40.2 (1.0-517.0) | 0.812 |
| EGIL classification: ALL/BAL | 67/10 | 40/5 | 27/5 | 0.561 |
| ACAs (yes/no) | 47/30 | 25/20 | 22/10 | 0.242 |
| BCR/ABL1- P190/P210 | 51/26 | 34/11 | 17/15 | 0.040 |
| ABL1 gene mutations (yes/no) (n=35)* | 29/6 | 20/2 | 9/4 | 0.100 |
| Allo-HSCT (yes/no) | 53/24 | 34/11 | 19/13 | 0.131 |
Abbreviations: TKI, tyrosine kinase inhibitor; WBC, white blood cell; EGIL, European Group for the immunological classification of leukemias; ACA, additional chromosomal abnormality; Allo-HSCT, allogeneic hematopoietic stem cell transplantation.
*35 patients were available for ABL1 mutation detection. Among the 6 patients with ABL1 gene mutations, no T315I mutation was found.